High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia

Chen, Shu Huey; Liang, Der Cherng; Liu, Hsi‐Che

doi:10.1002/(sici)1096-8652(199805)58:1<20::aid-ajh4>3.0.co;2-2

Cited by 12 publications

(6 citation statements)

References 22 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective study in 17 children with acute lymphoblastic or myelogenous leukaemia (AML), G‐CSF significantly reduced the use of antibiotics (17 versus 8 d, P = 0·0006) and hospitalization (37 versus 17 d, P = 0·0001) (Chen et al , 1998). While two patients of the control group died of sepsis and pneumonia, none of the G‐CSF treated patients died.…”

Section: A Haematopoietic Growth Factors In Paediatric Cancer Patientsmentioning

confidence: 99%

Haematopoietic Growth Factors in Children With Neutropenia

Lehrnbecher

Welte

2002

Br J Haematol

View full text Add to dashboard Cite

Section: A Haematopoietic Growth Factors In Paediatric Cancer Patientsmentioning

confidence: 99%

Haematopoietic Growth Factors in Children With Neutropenia

Lehrnbecher

Welte

2002

Br J Haematol

View full text Add to dashboard Cite

“…1 u. 2) [11,18,20,40,42,43,52,68,69,70,71,80,83,89,90,100,109,110]. In einem Teil der Studien führte die Gabe der Wachstumsfaktoren, wenn sie kurz nach Beendigung der jeweiligen Chemotherapieeinheiten, aber noch vor Beginn der Neutropenie begonnen wurde (¹primäre Prophylaxeª), neben einer Verkürzung der neutropenischen Phase auch zu signifikanten Verbesserungen anderer klinischer Parameter.…”

Section: G-csf Und Gm-csf In Der Primären Prophylaxeunclassified

“…In einer retrospektiven Studie bei 17 Kindern mit ALL und akuter myeloischer Leukämie (AML) zeigte sich ebenfalls ein positiver Effekt mit einer Verringerung von Antibiotikagaben (17 gegenüber 8 Tage, p = 0,0006) sowie einer Verkürzung des Krankenhausaufenthaltes (37 gegenüber 17 Tage, p = 0,0001) [18]. Zwei Kinder der Kontrollgruppe ohne G-CSF-Gaben verstarben an einer Sepsis bzw.…”

Section: G-csf Und Gm-csf In Der Primären Prophylaxeunclassified

Hämatopoetische Wachstumsfaktoren in der Infektionsprävention bei Kindern mit hämatologisch-onkologischen Erkrankungen

Lehrnbecher

2001

Klin Padiatr

View full text Add to dashboard Cite

The hematopoietic colony-stimulating factors have been introduced into clinical practice as additional supportive measures that can reduce, but not eliminate infectious complications associated with therapy-induced neutropenia. Over the past decade, we have begun to appreciate the subtler aspects of the proper use of G-CSF and GM-CSF, identifying appropriate indications and contraindications. In the course of evaluating the multitude of studies, a set of formal recommendations have been propagated for the judicious use of these expensive growth factors. To prevent serious infection, the use of G- or GM-CSF is recommended in a subset of pediatric cancer patients shortly after receiving chemotherapy or a marrow transplant. Children with intensive chemotherapy (e.g., children with high risk ALL, NHL or metastatic neuroblastoma) seem to benefit from hematopoietic growth factors whereas it is not clear that this applies to children undergoing therapy for solid tumors such as rhabdomyosarcoma or Ewing's sarcoma. An exciting development is the use of G-CSF and GM-CSF to mobilize peripheral-blood progenitor cells. Future studies in pediatric cancer patients are clearly warranted to address several issues. Prospective clinical trials are still needed to define specific treatment groups who can benefit from growth factor support. In this regard, efforts must be directed at better defining the endpoints and in particular, assigning value to reduction in treatment of possible infectious complications, such as days in hospital, antibiotic usage and costs. In addition, randomized studies are required to evaluate the proper dosage and duration of therapy, which most likely will vary between groups, depending upon underlying malignancy and therapy given. In addition, combinations of different growth factors have to be tested, particularly if ex vivo expansion and the storage of hematopoietic stem cells are to be utilized in a wider spectrum of patients.

show abstract

“…4 u. 5) [22,37,40,82,88,91,108,129,132,133,134,155,160,171,172,193,205,207]. In einem Teil der Studien führte die Gabe der Wachstumsfaktoren, wenn sie kurz nach Beendigung der jeweiligen Chemotherapieeinheiten, aber noch vor Beginn der Neutropenie begonnen wurde (¹primäre Prophylaxeª), neben einer Verkürzung der neutropenischen Phase auch zu signifikanten Verbesserungen anderer klinischer Parameter.…”

Section: G-csf Und Gm-csf In Der Primären Prophylaxeunclassified

Hämatopoetische Wachstumsfaktoren in der Prophylaxe und Therapie infektiöser Komplikationen bei Kindern mit Neutropenie

Lehrnbecher¹

2001

Klin Padiatr

View full text Add to dashboard Cite

Hematopoietic colony-stimulating factors have been introduced into clinical practice as additional supportive measures to reduce infectious complications associated with congenital or acquired neutropenia. Over the past decade, we have begun to appreciate the subtler aspects of the proper use of G-CSF and GM-CSF, identifying appropriate indications and contraindications. In the course of evaluating the corpus of studies, a set of formal recommendations have been propagated for the judicious use of these expensive growth factors. To prevent serious infection, the use of G-CSF or GM-CSF is recommended in a subset of pediatric cancer patients shortly after having received chemotherapy or a form of a marrow transplant. Children with highly intensive chemotherapy (e.g., children with high risk ALL or NHL) seem to benefit from hematopoietic growth factors whereas this is still unclear for children undergoing therapy for solid tumors. An exciting development is the use of G-CSF and GM-CSF to mobilize peripheral-blood progenitor cells for autologous or allogeneic transplantation. In pediatric patients with hematological diseases, there are only few data on the use of hematopoietic growth factors in children with myelodysplastic syndrome. Experts recommend the early administration of G-CSF in children with very severe aplastic anemia. The use of G-CSF is also recommended in children with severe chronic neutropenia, but these patients have to be monitored regularly for cytogenetic abnormalities. No larger study has shown a clinical benefit of hematopoietic growth factor in preterm or term infants. Future studies in pediatric patients are clearly warranted to address several issues. Prospective clinical trials are still needed to define specific treatment groups who can benefit from growth factor support. In this regard, efforts must be directed at better defining the endpoints and in particular assigning value to reduction in treatment of possible infectious complications, such as days in hospital, antibiotic usage and costs. In addition, randomized studies are required to evaluate the proper dosage and duration of therapy, which most likely will vary between groups of patients. In addition, combinations of different growth factors have to be tested, particularly if ex vivo expansion and the storage of hematopoietic stem cells are to be utilized in a wider spectrum of patients.

show abstract

High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia

Cited by 12 publications

References 22 publications

Haematopoietic Growth Factors in Children With Neutropenia

Haematopoietic Growth Factors in Children With Neutropenia

Hämatopoetische Wachstumsfaktoren in der Infektionsprävention bei Kindern mit hämatologisch-onkologischen Erkrankungen

Hämatopoetische Wachstumsfaktoren in der Prophylaxe und Therapie infektiöser Komplikationen bei Kindern mit Neutropenie

Contact Info

Product

Resources

About